EG-1962 (nimodipine microparticles)

DRUG2 trials

Sponsors

Edge Therapeutics Inc

Conditions

Subarachnoid Hemorrhage, Aneurysmal

Phase 1

Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

TerminatedNCT02893826

Edge Therapeutics IncSubarachnoid Hemorrhage, Aneurysmal

Start: 2016-09-30End: 2018-03-31Updated: 2018-07-26

Phase 3

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

TerminatedNCT02790632

Edge Therapeutics IncSubarachnoid Hemorrhage, Aneurysmal

Start: 2016-07-31End: 2018-06-30Target: 374Updated: 2018-07-26

Related Papers

Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease

Human Gene Therapy2023-08-259 citations

Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage

Stroke2020-03-1869 citations

Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].

2019-02-0119 citations

Intraventricular Nimodipine for Aneurysmal Subarachnoid Hemorrhage: Results of the NEWTON Phase 1/2a Study

Neurosurgery2017-04-204 citations